The surge in Alembic Pharma share price came after the company announced that it has received US Food & Drug Administration (USFDA) final approval for Betamethasone Valerate Foam, 0.12 per cent.
The IPO comprises a fresh issue of 41.8 million shares valued at Rs 397.1 crore and an offer for sale (OFS) of 11.9 million shares worth Rs 113.05 crore.